Plasmalogens in human serum positively correlate with high-density lipoprotein and decrease with aging

Journal of Atherosclerosis and Thrombosis

Volumn 14, Issue 1, 2007, Pages 12-18

  Maeba, Ryouta ^a   Maeda, Tomomi ^a   Kinoshita, Makoto ^a   Takao, Kosuke ^a   Takenaka, Hideki ^a   Kusano, Jyun ^a   Yoshimura, Nakayuki ^a   Takeoka, Yoko ^a   Yasuda, Daijiro ^a   Okazaki, Tomoki ^a   Teramoto, Tamio ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antioxidant; Apolipoprotein A I; LDL particle size; Small dense LDL

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CHOLINE PLASMALOGENS; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDAL ETHANOLAMINES; PLASMALOGEN; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ARTICLE; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; HUMAN; MALE; MIDDLE AGED;

ADULT; AGED; AGING; APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PLASMALOGENS;

EID: 34249848928     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.14.12     Document Type: Article

References (27)

1. Brautigam C, Engelmann B, Reiss D, Reinhardt U, Thiery J, Richter WO, and Brosche T: Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL apheresis. Atherosclerosis, 1996; 119:77-88
2. Felde R and Spiteller G: Plasmalogen oxidation in human serum lipoproteins. Chem Phys Lipids, 1995; 76:259-267
3. Vance JE: Lipoproteins secreted by cultured rat hepatocytes contain the antioxidant 1-alk-l-enyl-2-acylglycerophosphoethanolamine. Biochim Biophys Acta, 1990; 1045:128-134
4. Yavin L and Gatt S: Oxygen-dcpcndent cleavage of the vinyl-ether linkage of plasmalogens. Eur J Biochem, 1972; 25:431-446
5. Zoeller RA, Morand OH, and Raetz CRH: A possible role for plasmalogens in protecting animal cells against photosensitized killing. J Biol Chem, 1988; 263:11590-11596
6. Zoeller RA, Lake AC, Nagan N, Gaposchkin DP, Legner MA, and Lieberthal W: Plasmalogens as endogenous anti-oxidants: somatic cell mutants reveal the importance of the vinyl ether. Biochem J, 1999; 338:769-776
7. Engelmann B, Brautigam C, and Thiery J: Plasmalogen. phospholipids as potential protectors against lipid peroxidation of low density lipoproteins. Biochem Biophys Res Commun, 1994; 204:1235-1242
8. Maeba R and Ueta N: Ethanolamine plasmalogen and cholesterol reduce the total membrane oxidizability measured by the oxygen uptake method. Biochem Biophys Res Commun, 2003; 302:265-270
9. Brosche T: Plasmalogen phospholipids-facts and theses to their antioxidative qualities. Arch Gerontol Gefiatr, 1997; 25:73-81
10. Brosche T: Plasmalogen levels in serum from patients with impaired carbohydrate or lipid metabolism and in elderly subjects with normal metabolic values. Arch Gerontol Geriatr, 2001; 32:283-294
11. -). Anal Biochem, 2004; 331:169-176
12. Bligh EG and Dyer WJ: A rapid method of total extraction and purification. Can J Biochem Physiol, 1959; 31:911-917
13. Chalvardjian A and Rudnicki E: Determination of lipid phosphorus in the nanomolar range. Anal Biochem, 1970; 36:225-226
14. Nichols AV, Krauss RM, and Musliner TA: Nondenaturing polyacrylamide gradient gel electrophoresis. Methods enzymol, 1986; 128:417-431
15. Friedewald WT, Levy RI, and Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem, 1972; 18:499-502
16. Kinoshita M, Kojima M, Matsushima T, and Teramoto T: Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin Chim Acta, 2005; 351:115-120
17. Maruyama C, Imamura K, and Teramoto T: Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb, 2003; 10: 186-191
18. Staels B and Auwerx J: Regulation of apo A-I gene expression by fibrates. Atherosclerosis, 1998; 137:19-23
19. Schoonjans K, Staels B, and Auwerx J: The peroxisome proliferators; activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta, 1996; 1302:93-109
20. Hayashi H and Oohashi M: Incorporation of acetyl-CoA generated from peroxisomal beta-oxidation into ethanol- amine plasmalogen of rat liver. Biochim Biophys Acta, 1995; 1254:319-325
21. Hayashi H and Takahata S: Role of peroxisornal fatty acyl-CoA β-oxidation in phospholipid biosynthesis. Arch Biochem Biophys, 1991; 284:326-331
22. Wei H, Kemp S, McGuinness MC, Moser AB, and Smith KD: Pharmacological induction of peroxisomes in peroxisome biogenesis disorders. Ann Neurol, 2000; 47:286-296
23. Mandel H, Sharf R, Berant M, Wanders RJ, Vreken P, and Aviram M: Plasmalogen phospholipids are involved in HDL-mediated cholesterol efflux: insights from investigations with plasmalogen-deficient cells. Biochem Biophys Res Commun, 1998; 250:369-373
24. Maeba R and Ueta N: Ethanolamine plasnialogen prevent the oxidation of cholesterol by reducing the oxidizability of cholesterol in phospholipids bilayers. J Lipid Res, 2003; 44:164-171
25. Nagan N and Zoeller RA: Plasmalogens: biosynthesis and functions. Prog Lipid Res, 2001; 40:199-229
26. Poynter ME and Daynes RA. Perokisome proliferators-activated receptor a activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem, 1998; 273:32833-32841
27. Erol A: PPARalpha activators may be good candidates as antiaging agents. Med hypotheses, 2005; 65:35-38